Institute for Ophthalmic Research
Molecular Biology of Retinal Degenerations

Director: Prof. Dr. Marius Ueffing
University of Tübingen
Centre for Ophthalmology
Elfriede-Aulhorn-Straße 7
72076 Tübingen
Germany
Phone: +49 7071 29 84021
Fax: +49 7071 29 4560
E-mail: info@eye-tuebingen.de
Web: www.eye-tuebingen.de/ueffinglab

Research Topics

• Age-Related Macular Degeneration (EU-Consortium EYE-RISK; www.eyerisk.eu)
• Retinal Degeneration (FFB Research Center Consortium PHOTORECEPTOR PROTEOSTASIS)
• Epidemiology & Automated Reading: German National Cohort (NAKO): Coordination Competence Platform ‘Eye’ (www.nako.de)
• Ciliopathies (EU-Consortium SYSCILIA; www.syscilia.org)
• Therapy Development; Ocular Drug Delivery (EU-Consortium OCUTher; www.ocughter.eu)

Related Projects:
• EYE-RISK - European Union’s Horizon 2020 research and innovation programme Exploring the combined role of genetic and non-genetic factors for developing Age-Related Macular Degeneration: A systems level analysis of disease subgroups, risk factors, and pathways.
• OcUTher - European Union’s Horizon 2020 Innovative Training Networks (ITN) Educational network in ocular drug delivery and therapeutics.
• Targeting Proteostasis and Protein Quality Control in Photoreceptors / Towards Therapeutic Intervention - Foundation Fighting Blindness Research Center Program Project Award (PPA) Study of disruption of proteostasis in inherited retinal to develop targeted treatments.
• CURETINA - Excellence Initiative Grant, Personalized Medicine: Personalized medicine for hereditary retinal dystrophies.

Contact

Ueffing Lab
Molecular Biology of Retinal Degenerations

How to find us:

© Institute for Ophthalmic Research - February 2017
Our research is focused on disease mechanisms in neurodegenerative diseases, on processes driving neurodegeneration as well as on mechanisms of retinal neuroprotection. We aim to develop diagnostics and therapies for retinal degenerations. Our group is teaming up with computational scientists and structural biologists to develop and apply molecular and bioanalytical strategies towards functional analysis of protein complexes and protein networks in disease. In a long-term attempt to understand retinal physiology, we study cellular signaling pathways conferring cellular integrity and longevity.

At the analytical and technical level, we apply and develop multi-omic workflows with an emphasis on advanced proteomics. We have developed a new generation of patented tandem affinity tags allowing fast and efficient complex purification without involving proteolytic cleavage of the tag and advanced mass-spectrometry to identify and analyse protein interactions and signaling. Applying various computational modeling approaches, we analyse patterns of molecular, physiological and histological perturbation linked to disease. Towards advanced ophthalmological reading, we develop algorithms to automatically analyze retinal images.

Our methodology spectrum also includes custom organotypic culture systems and intraocular delivery of compounds (small molecule and peptides) using animal models that naturally bear or closely mimic retinal diseases occurring in humans.

### Research Areas

- Pathomechanisms & Risk Factors
- Innovative Therapy-Development
- Multimodal Diagnostics for Personalised Medicine

### Retinal Degeneration

Vision is crucial for mastering and enjoying life. Vision highly depends on retinal function. A large variety of diseases that are either inherited or acquired disrupt normal physiology of retinal cells. If this disruption persists for a sustained period of time, retinal cells undergo irreversible degeneration. Thus, if not stopped, retinal degeneration eventually results in vision impairment and blindness.

Impaired vision and blindness deeply affect the quality of life. Current understanding of retinal degeneration does not go far enough to offer effective therapies. Work carried out in our group aims to elucidate the mechanisms that maintain retinal function in order to gain a better understanding of retinal degeneration.

Within several large-scale consortium projects, we take part in joint efforts to define risks for retinal degeneration, generate diagnostics and develop new avenues for therapy.

---

**Marius Ueffing**
- Professor, Dr. rer. nat.
- Director of the Institute for Ophthalmic Research
- Head of Molecular Biology of Retinal Degenerations

**Karsten Boldt**
- Dr. rer. nat.
- Senior Staff Scientist